-
Holding 3 clinical approval documents in hand, participating in the formulation of US Pharmacopoeia industry standards... Triassic opens a new era of 3D printing drugs
Time of Update: 2021-11-15
0 era opening strategy: through opening up technical resources, establishing a relationship with global pharmaceutical companies To realize the commercialization of 3D printing drug technology .
-
Express|To make tumor cells "nowhere to escape", Takeda announces the acquisition of γδT cell therapy platform
Time of Update: 2021-11-15
This acquisition expands Takeda’s combined pipeline of immuno-oncology and innate immune cell therapy to develop potential therapies for solid tumors and hematological malignancies .
" Reference materials: [1] Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors.
Retrieved October 27, 2021, from https:// -GammaDelta-Therapeutics-to-Accelerate-Development-of-Allogeneic-%CE%B3%CE%B4T-Cell-Therapies-Addressing-Solid-Tumors
-
Targeting the global pattern of CTLA-4 R&D, Chinese companies are in a favorable position
Time of Update: 2021-11-15
Figure 9 China's CTLA-4 product phase distribution (source: public information, Fengshuo Ventures; only statistics clearly indicate trials with specific indications; * is the top 10 cancer types in China) The differences in the development of CTLA-4 drugs between China and the United States have created three major opportunities for domestic companies.
-
CDE priority review analysis in the first three quarters of 2021
Time of Update: 2021-11-15
3) Vaccines and innovative vaccines urgently needed for disease prevention and control; 4) Drugs included in the breakthrough therapeutic drug program; 5) Drugs that meet the conditions of approval; 6) The State Drug Administration stipulates other priority review and approval situations .
-
Demand dividend continues to be released. Digital healthcare is ushering in the best era!
Time of Update: 2021-11-15
Digital medical content continues to develop along with technological advances, making medical equipment, medical network systems, and medical system-related services more intelligent, providing more efficient integrated services, and helping to improve the service capabilities of medical institutions .
-
The revival of therapeutic tumor vaccines! What are the results of the clinical trials of the mRNA vaccine giants?
Time of Update: 2021-11-15
Vaccines against human papillomavirus (HPV) and hepatitis B virus have been successfully applied to the prevention of related tumors . In contrast, the development of therapeutic tumor vaccines is
-
FDA persuades Agenus to withdraw, PD-1 is getting more and more difficult to market in the United States
Time of Update: 2021-11-15
Earlier, drugs O and K have passed accelerated drug approval for the treatment of metastatic small cell lung cancer, but due to poor efficacy data in the past two years, they were dismissed by the FDA .
-
The 2021 Hurun Report is released!
Time of Update: 2021-11-15
78%; the net profit attributable to shareholders of listed companies was 722 million yuan, a year-on-year increase of 195.
48%; net profit attributable to parent company was 888 million yuan, a year-on-year increase of 2.
-
Interpretation of "In Vitro Diagnostic Reagent Classification Rules"
Time of Update: 2021-11-15
" Articles 8 and 9 are based on the new "Regulations" and "In Vitro Diagnostic Reagent Registration and Filing Management Measures", with reference to Order 15, clarifying the formulation and adjustment of the in vitro diagnostic reagent classification catalog and the confirmation of newly developed product categories .
-
Internet diagnosis and treatment prohibits unified prescriptions and supplements!
Time of Update: 2021-11-15
The draft opinion clarifies that medical institutions should strictly abide by prescription management regulations such as the "Prescription Management Measures" when carrying out Internet diagnosis and treatment activities, strengthen drug management, and prohibit problems such as unified prescriptions and supplements .
-
Zejing Pharmaceuticals: Donafinil has sales of nearly 100 million yuan in more than 100 days, and the company's commercialization capabilities have been initially verified by the market
Time of Update: 2021-11-15
Zejing Pharmaceuticals said that the company is vigorously promoting Donafinil to enter various guides and insurance catalogs, which is expected to benefit more liver cancer patients .
-
Merck's new crown oral drug will soon be approved by the European Union
Time of Update: 2021-11-15
Merck's oral new crown treatment drug Molnupiravir (Molnupiravir) The European Medicines Agency stated that the decision to initiate the rolling review was based on preliminary results of laboratory and clinical studies .
-
What are the investment opportunities in the medical insurance negotiations in 2021?
Time of Update: 2021-11-15
Looking back on the past three years, medical insurance negotiations have achieved excellent results, including more than 200 new varieties, and through negotiations, the price of drugs has been greatly reduced, and the availability of drugs has been improved .
-
With the advent of gene therapy era, how can the most expensive therapy get medical insurance?
Time of Update: 2021-11-15
In May 2019, the Japan Central Social Insurance Medical Council approved the inclusion of CAR-T cell therapy product Kymriah in medical insurance, with a price of approximately 33.
-
Wang Yongjun's team CHANCE-2 climbs to the top of NEJM to guide new strategies for secondary stroke prevention Interview with authors
Time of Update: 2021-11-15
On October 28, 2021, the New England Journal of Medicine (NEJM) published online the CHANCE-2 study results of Professor Wang Yongjun’s team from Beijing Tiantan Hospital, Capital Medical University In patients with CYP2C19 inactivated alleles, ticagrelor combined with aspirin is more effective than clopidogrel combined with aspirin in preventing stroke recurrence.
-
The development of new coronavirus pneumonia vaccines and therapeutic drugs
Time of Update: 2021-11-15
According to the Cortellis database, as of September 26, 2021, there are hundreds of new coronary pneumonia neutralizing antibody drugs under research worldwide, and 23 are in the clinical development stage (Table 2) .
-
A new breakthrough in first-line cholangiocarcinoma!
Time of Update: 2021-11-15
On October 25th, AstraZeneca announced that its PD-L1 monoclonal antibody duvalizumab (Imfinzi) combined with chemotherapy for the first-line treatment of advanced biliary tract cancer (BTC) in Phase III clinical TOPAZ-1 achieved overall survival in the interim analysis The primary end point of the period (OS) .
-
Hengrui, Chia Tai Tianqing, Kangfang... 66 new drugs have been approved for clinical use!
Time of Update: 2021-11-15
BIOTEC and Dongyao sprint; 30 billion PPI drug market, domestically produced Class 1 new drugs are reported for production; The new drugs of Zhengda Tianqing, Kangfang and Poinsettia were approved for clinical use; "Innovative Drug One Brother" broke out!
-
Q3 The latest financial report: What breakthroughs have Novartis and Eli Lilly have in the development of innovative therapies?
Time of Update: 2021-11-15
Kisqali is being used as an adjuvant therapy in phase 3 clinical trials to treat patients with early HR-positive and HER2-negative breast cancer In addition, the ABL1 allosteric inhibitor asciminib developed by the company has been granted priority review by the US FDA for the treatment of patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) .
-
Another breakthrough!
Time of Update: 2021-11-15
The Xinkening bivalent human papillomavirus vaccine has been pre-certified by the World Health Organization, becoming the sixth pre-certified domestic vaccine in China, marking that China’s vaccine product supervision, development and production system and product quality have achieved international standards.